AVTR · Avantor
Conviction · Medium · more likely to lead the S&P 500 over the next three months, by a modest margin
Wrong if: a weekly close below $14.00
Note written ·
Price against the kill line
11.0% clear of its kill line on the 13 November 2026 close.
How to read this
The red mark is the price level of the published kill line: a close through it (a weekly close, on a weekly line) would prove the research note wrong on price. The dot is where the stock closed on 13 November 2026; a dot left of the mark has closed through its line.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a weekly close below $14.00, on record since 10 November 2026; only a weekly close settles it. The shares are up 15.1% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A weekly close below $14.00, under all four broker targets set on 29 October 2026 and the $14.77 MarketBeat average, which would show the recovery has stalled. Q4 2026 organic growth below the implied 2.5% low end, or a cut to FY2026 adjusted EPS guidance, would also break the case.
Research onlyNot in the portfolio.
Catalyst
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 28 October 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 1,698
- Revenue, change on a year (%)
- +4.6
- Gross margin (%)
- 31.5
- Operating margin (%)
- 8.2
- Free cash flow, four quarters ($M)
- 439
- Net cash, cash less debt ($M)
- −3,220
- Price to earnings (×)
- 31.2
- Enterprise value to sales (×)
- 2.1
All filed numbers
What Avantor reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| first filed | 1,698 | +4.6 | 31.5 | 8.2 |
| first filed | 1,692 | +0.5 | 31.7 | 7.2 |
| first filed | 1,581 | 0.0 | 31.7 | 6.3 |
| first filed | 1,664 | −1.4 | 31.5 | 7.6 |
| first filed | 1,624 | −5.3 | 32.4 | −40.0 |
| first filed | 1,683 | −1.1 | 32.9 | 7.7 |
| Pre-tax income ($M) | 98.0 |
| Net income ($M) four quarters: 337 | 203 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | −0.1 |
| Operating cash flow ($M) | 585 |
| Capital spending ($M) | 146 |
| Free cash flow ($M) | 439 |
| Cash and short-term investments ($M) | 464 |
| Debt ($M) long-term debt | 3,684 |
| Net cash, cash less debt ($M) | −3,220 |
| Deferred revenue ($M) | Not reported |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | 1,123 |
| Inventory ($M) | 855 |
| Shareholders' equity ($M) | 5,836 |
| Market value ($M) | 10,530 |
| Enterprise value, market value plus net debt ($M) | 13,750 |
| Enterprise value to sales (×) | 2.1 |
| Enterprise value to operating income (×) | 28.2 |
| Price to earnings (×) | 31.2 |
| Price to book value (×) | 1.8 |
| Free-cash-flow yield (%) | 4.2 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 5.1% of shares outstanding sold short, 4.6 days of average trading to cover, −11.9% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $0 |
| 12 monthsfrom | $7.6M | $0 |
The thesis
Avantor's lab-supply volumes are growing again, and management raised its full-year outlook on 28 October 2026. Distribution margins fell as volume came back, though. The 8 December 2026 Investor Day in New York City settles the case. It shows whether management's multiyear targets include a path back to higher margins. The rating is Medium because growth has reached reported revenue, the Investor Day can add new information within four weeks, and the margin question is still open.
Third-quarter 2026 organic growth was 5.2%, after a 0.4% decline in the second quarter (Q2 and Q3 2026 earnings releases). The shares closed at $15.73 on 11 November 2026, up 13.6% over three months on adjusted daily closes. CEO Emmanuel Ligner announced the Investor Day on the Q2 2026 earnings call in August.
Company news since the report covers personnel only. Mikey Santiago was named Chief Information Officer on 26 October 2026. SEC Form 4 filings dated 3 November 2026 show restricted stock awards to two executives on 30 October 2026. Neither item touches growth or margins.
Bullish and bearish views on Avantor, Inc.
The bull case on Avantor, Inc. (AVTR), in brief: both segments returned to organic growth. The bear case: distribution margins are shrinking.
Bull case
- Both segments returned to organic growth. VWR Distribution & Services grew 5.8% organically to $1,233.8 million in Q3 2026 (Q3 2026 earnings release, 28 October 2026). Bioscience & Medtech Products grew 3.6% to $464.5 million at a 26.6% adjusted operating margin, after a 5.6% organic decline in Q2.
- Guidance implies growth continues. FY2026 organic growth guidance rose to +0.75% to +1.25%, from −0.5% to +0.5% (Q3 2026 release). On the 28 October 2026 call, management said the full-year range implies Q4 organic growth of 2.5% to 4.5%.
- Cash flow is cutting debt. Adjusted net leverage fell to 3.1 times at 30 September 2026, from 3.3 times at 30 June 2026. Management targets below 3 times by year-end 2026. FY2026 free cash flow guidance narrowed to $525–$550 million, from $500–$550 million (Q3 2026 release and call).
- Post-report targets sit above the shares. On 29 October 2026, Benzinga reported RBC raising its target to $17 from $14 and Stifel to $18 from $15. Baird set $18 and Barclays $16. All four are above the 11 November 2026 close of $15.73.
Bear case
- Distribution margins are shrinking. VWR's adjusted operating margin fell to 9.7% in Q3 2026 from 11.2% a year earlier. On the 28 October 2026 call, management blamed product mix, inflation and growth investment. It also said year-to-date pricing of 1%–2% still trails inflation.
- Margin guidance did not move. FY2026 adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) margin guidance stayed at 14.8%–15.3% while growth guidance rose. Q3 adjusted EBITDA was $256.9 million at a 15.1% margin, against $267.9 million at 16.5% a year earlier. Quiver Quant reported the shares down 4.3% on 28 October 2026 and tied the fall to the small guidance increase.
- The consensus leans Hold. On 4 November 2026, MarketBeat counted two buy, 13 hold and one sell rating. Its average target of $14.77 is below the 11 November 2026 close of $15.73. Of the four brokers that moved on 29 October 2026, only Baird rates the shares a buy, and Barclays stays at Underweight.
- GAAP leverage looks much heavier. At 30 September 2026, the Q3 release shows GAAP net leverage of 9.6 times against 3.1 times adjusted. Gross debt was $3,699.7 million and cash was $464.3 million. Equity holders carry that debt through any slowdown in lab spending.
Price setup
The shares closed at $15.73 on 11 November 2026. That is 9.9% below the 52-week intraday high of $17.45 set on 22 October 2026, the week before the Q3 report. The 52-week closing low was $7.41 on 27 March 2026, so the shares have roughly doubled from that low.
The 50-day moving average was $15.67 and the 200-day moving average $11.34 on 11 November 2026 (adjusted daily closes). The shares sit just above the 50-day average and far above the 200-day average. Closes between 4 November 2026 and 11 November 2026 stayed in a range of $15.14 to $15.91.
The price already reflects a recovery in volumes: the shares rose 13.6% over three months to 11 November 2026, and they trade above the MarketBeat average target of $14.77 (4 November 2026). The next move depends on margin targets, which the 8 December 2026 Investor Day sets out.
Insider activity in SEC Form 4 filings is compensation-related. Claudius Sokenu, Chief Legal and Compliance Officer, received 62,305 shares and Brittany Hankamer, Chief HR Officer, received 46,728 shares in awards on 30 October 2026. The most recent disposal was CEO Emmanuel Ligner's 29,803 shares withheld for tax at $13.33 on 18 August 2026, which is not an open-market sale.
Catalysts ahead
- 8 December 2026: Investor Day, New York City: multiyear strategy, segment detail, capital allocation and financial objectives. Shows whether medium-term targets include a recovery from the 9.7% VWR operating margin, the main open question after the Q3 volume rebound.
- ~5 February 2027 (est.): Q4 2026 report and first FY2027 guidance. Tests the implied Q4 organic growth of 2.5%-4.5% and the below-3x leverage target, and sets the 2027 growth and earnings outlook.
What would change the view
A weekly close below $14.00, under all four broker targets set on 29 October 2026 and the $14.77 MarketBeat average, which would show the recovery has stalled. Q4 2026 organic growth below the implied 2.5% low end, or a cut to FY2026 adjusted EPS guidance, would also break the case.
The risks this note tracks, each with what would confirm it:
- Distribution margins keep shrinking as growth comes from lower-margin volume and pricing trails inflation. Confirmed by: VWR adjusted operating margin below 9.7% in Q4 2026, or Investor Day targets with no margin recovery path.
- The Q3 2026 volume rebound proves to be a one-quarter catch-up. Confirmed by: Q4 2026 organic growth below the 2.5% low end of the implied range, or VWR organic growth below mid-single digits.
- A Hold-heavy consensus attracts little new buying, with the MarketBeat average target of $14.77 below the shares. Confirmed by: no rating upgrades after the 8 December 2026 Investor Day, or broker targets cut after it.
- Deleveraging stalls, keeping the equity exposed to rates and refinancing costs. Confirmed by: adjusted net leverage at or above 3.0x at year-end 2026, or FY2026 free cash flow below $525M.
What it trades with
Avantor sells lab consumables, chemicals and bioprocessing materials to drug makers, academic labs and industry. The shares tend to move with life-science tools and lab-distribution peers on news about biopharma budgets and research funding. Its VWR channel competes directly with Thermo Fisher's Fisher Scientific distribution business.
Adjusted net leverage of 3.1 times (30 September 2026) adds sensitivity to interest rates and credit conditions. Less indebted peers carry less of that exposure.
The evidence, claim by claim (8)
- Q3 2026 net sales were $1,698.3M, up 4.6% reported and 5.2% organic. Adjusted EPS was $0.22 against a $0.21 consensus, and diluted GAAP EPS was $0.30. Avantor Q3 2026 earnings release (Form 8-K exhibit 99.1) · as of
- VWR Distribution & Services grew 5.8% organically to $1,233.8M, while its adjusted operating margin fell to 9.7% from 11.2% a year earlier. Avantor Q3 2026 earnings release (Form 8-K exhibit 99.1) · as of
- Avantor raised FY2026 guidance: organic growth to +0.75% to +1.25%, adjusted EPS to $0.81-$0.83 and free cash flow to $525-$550M. Adjusted EBITDA margin guidance stayed at 14.8%-15.3%. Avantor Q3 2026 earnings release (Form 8-K exhibit 99.1) · as of
- Q3 2026 adjusted EBITDA was $256.9M at a 15.1% margin, against $267.9M at a 16.5% margin a year earlier. Avantor Q3 2026 earnings release (Form 8-K exhibit 99.1) · as of
- Management said the full-year range implies Q4 2026 organic growth of 2.5%-4.5%. Avantor Q3 2026 earnings call · as of
- Adjusted net leverage was 3.1x and GAAP net leverage 9.6x, on $3,699.7M gross debt and $464.3M cash. Management targets adjusted leverage below 3x by year-end 2026. Avantor Q3 2026 earnings release and call · as of
- On 29 October 2026, RBC raised its target to $17 from $14 (Sector Perform), Stifel to $18 from $15 (Hold), Baird to $18 (Outperform) and Barclays to $16 (Underweight). Benzinga analyst ratings headlines · as of
- MarketBeat counted two buy, 13 hold and one sell rating on Avantor, with a $14.77 average price target. MarketBeat, 4 November 2026 report · as of
Sources
- Avantor, Inc. - Form 8-K - FY2026 · sec.gov ·
- Avantor Q2 Earnings Call Highlights · finance.yahoo.com
- Avantor (AVTR) Q2 2026 Earnings Call Transcript · fool.com ·
- Avantor, Inc. $AVTR Stock: ARGA Investment Management LP Decreases Holdings · marketbeat.com ·
- Avantor Falls Despite Q3 Beat as Guidance Lift Looks Limited · quiverquant.com
Related · shared themes
AZTA
Azenta
Azenta is more likely to beat the S&P 500 over three months because its fiscal 2027 plan, issued 10 November 2026, adds 3% to 5% organic…
CRL
Charles River Laboratories International
Charles River Laboratories' preclinical recovery passed its 4 November 2026 test with 4.7% organic growth, a 1.09 book-to-bill and raised…
EMBC
Embecta
Embecta Corp. shares are modestly favored to beat the S&P 500 as higher margins and debt repayment outweigh shrinking U.S. pen-needle…
ENOV
Enovis
Enovis Corporation's orthopedic turnaround passed its 5 November 2026 test with 4.6% organic growth, raised earnings guidance and a $200…
See also · stocks to watch